Jerini AG Reaches Agreement to Sell JPT Peptide Technologies to TheraCode
News May 04, 2009
Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz.
Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in cash. The sale of JPT Peptide Technologies GmbH to TheraCode GmbH is a further achievement in the implementation of Jerini AG's strategic decision published on October 10, 2008 to divest all non-strategic businesses and to focus on the core business Firazyr.
Protein Structure Advances Diabetes and Parkinson's ResearchNews
The 3-D structure of a protein with links to several different areas of disease research has been detailed for the first time.READ MORE